(Q33338891)

25 July 2017

title

Association of eptifibatide and acute profound thrombocytopenia (English)

1 reference

25 July 2017

1 reference

R H Hongo

1

1 reference

25 July 2017

B N Brent

series ordinal

2

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

American Journal of Cardiology

25 July 2017

published in

1 reference

25 July 2017

volume

88

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

428-431

1 reference

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Eptifibatide in acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901695-2

10.1016/S0002-9149(01)01695-2

7 January 2021

Identifiers

DOI

1 reference

25 July 2017

1 reference